Tmunity Therapeutics, Inc., a private, clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced an additional $35 million Series A investment from Kleiner Perkins and...
Intact Vascular Announces $20 Million Series C Financing to Fund Company through PMA Approval of the Tack Endovascular System®
“We continue to be impressed with the extensive clinical program that Intact Vascular is advancing to illustrate the significant clinical benefits that a better solution for dissections can have on angioplasty for peripheral arterial disease and critical limb ischemia,” said Justin Klein, MD, JD, Partner at New Enterprise Associates and member of the Intact Vascular Board of Directors.
To date, Inari Medical has developed the FlowTriever and ClotTriever Systems, both of which are designed to enable the safe removal of large clot volumes from big vessels without the use of thrombolytic drugs.
3/28/18: Network of eminent high net worth individuals join financing syndicate and other highlights!
TAE Life Sciences to Develop Groundbreaking Therapy for Difficult-to-Treat Cancers, including Head, Neck and GBM; Announces $40 Million Series A Funding
3/12/18: The company Becomes First to License TAE Technologies' Accelerator-based Beam Technology for Clinical Investigation
MetactiveMedical Raises $1.2 Million of Additional Capital and Awarded $1.5 Million Grant from the National Institutes of Health
This new investment capital and grant funding will be used to continue the development of our novel platform of embolic products, which we believe will provide physicians with devices that are exceptionally deliverable, can be placed with a high level of precision, are resistant to migration, and provide immediate, complete, and lasting occlusion,” stated F. Nicholas Franano, MD, President and CEO of Metactive.
HeartFlow has made significant progress in developing and commercializing its pioneering non-invasive technology.
A $4M grant was awarded to support transfer to manufacturing of MeMed's pioneering point of care platform that distinguishes bacterial from viral infections